There are currently 47 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Carcinoma, Non-Small-Cell Lung participants are California, Texas, Florida and New York.
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer
NCT05068024
Recruiting
The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2022
Locations: Gabrail Cancer Center, Canton, Ohio +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249
Recruiting
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Massachusetts General Hospital ., Boston, Massachusetts +13 locations
Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Register for Updates
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
NCT05462873
Recruiting
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University Of California LA Santa Monica Location, Los Angeles, California +10 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Register for Updates
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798
Recruiting
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and three substudies. Each substudy will enroll a different population of NSCLC participants. The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 4 substudies. Participants mus... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +38 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
NCT05642195
Recruiting
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back. Objective: To test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Register for Updates
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Clearview Cancer Institute, Huntsville, Alabama +370 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654
Recruiting
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Atlanta, Georgia +27 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314
Recruiting
The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD[s]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama +76 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786
Recruiting
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +9 locations
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428
Recruiting
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of California at San Diego, La Jolla, California +108 locations
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: City of Hope, Duarte, California +67 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
NCT05456256
Recruiting
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +7 locations
Conditions: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
Register for Updates